PhRMA Hill lobbying will be weakened by Nersesian departure, work environment investigation.
PhRMA CAPITOL HILL LOBBYING WILL BE WEAKENED going into the crucial period for consideration of FDA reform. Two related events are likely to reduce the association's lobbying resources and to divert its attention from that task at the beginning of 1996. At the beginning of November, VP-Federal Legislation Lynda Nersesian announced her intention to leave the Pharmaceutical Research & Manufacturers of America at the end of the year. That resignation has precipitated an outside investigation of the work environment at the association and a distraction within the industry's Washington lobbying community.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth